Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Start Date
6/2/2021
Completion Date
7/9/2026
Summary
The over-arching aim of this study is to evaluate the effects of two specific anti-cancer chemotherapies, vincristine and doxorubicin, on bladder function and urine composition.
Detailed Description
The over-arching aim of this study is to evaluate the effects of two specific anti-cancer chemotherapies, vincristine and doxorubicin, on bladder function and urine composition. The global hypothesis is that childhood cancer survivors with prior exposure to systemic vincristine (VCR) and/or doxorubicin (DOX) report an increased incidence of bladder dysfunction (BD) symptoms on the Dysfunctional Voiding Symptom Score (DVSS) survey. We expect to observe differences in non-invasive urodynamic (niUDS) testing between childhood cancer survivors with BD symptoms on the DVSS versus those without BD symptoms on DVSS. We also expect to observe statistically significant differences in the urinary levels of known urinary biomarkers of BD (NGF, ATP and BDNF) of patients with evidence of BD compared to those without BD on the DVSS. We also expect to observe rational differences in the urinary proteome of patients between those with and without BD.
Eligibility Criteria
Age Range: 5 years to 13 years
Interventions
Non-invasive Urodynamic Test (niUDS)
Urinary proteomic screen
Dysfunctional Voiding Symptom Score Survey (DVSS)
Conditions
Locations
Children's Hospital Colorado
Aurora, Colorado 80045
United States